Polar Capital Funds PLC - Biotechnology Fund R Inc
Polar Capital Funds PLC (Open Ended Investment Company domiciled in Ireland)
Key Information
Legal Documents
Performance
Analysis

Fund Profile

Category: Open Ended Investment Company

Objectives The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies. Investment Policy The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (USD) benchmark as a performance target and to calculate the performance fee. Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors. You may sell your shares on days which banks are normally open

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Risk and reward profile
6
Lower Risk
Possible Lower
Returns
Higher Risk
Possible Higher
Returns
Key Information
Closing Price 24/09/202032.34
Morningstar categorySector Equity Biotechnology
CurrencyUSD
Distribution statusDistributing
ISINIE00B3XLHR60
Inception Date31/10/2013
Minimum initial amount100.00 USD
Fees And Charges
Entry feeNone
Custody feeNone
Exit feeNone
Ongoing charge1.67% of which 0.50% is paid to MeDirect
Fund management company
AddressPolar Capital LLP 16 Palace Street London SW1E 5JD United Kingdom
Manager NameDavid Pinniger
Manager Start Date31/10/2013
Websitewww.polarcapital.co.uk
Total Net Assets (mil)803.39 USD (31/08/2020)
UCITSYes
AdministratorNorthern Trust International Fund Administration Services (Ireland) Limited

Documents

Prospectus
en 22/06/2020
Annual Report
en 31/03/2019
Semi Annual Report
en 30/06/2019
Morningstar Report
28/09/2020

Performance

Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
The performance in euro can be lower or higher than the performance in the currency of denomination of the fund due to fluctuations in exchange rates.
Annualised performance in USD
PeriodAnnualised returnDate
1 year47.13%24/09/2020
3 years14.97%24/09/2020
5 years12.88%24/09/2020
Since launch18.54%24/09/2020
Cumulative performance in USD
Performance
YTD 01/01/202019.38
1 month2.67
3 months3.42
6 months48.69
Quarterly Returns
Q 1Q 2Q 3Q 4
2020-13.33%30.66%--
201918.73%-2.03%-12.49%28.45%
20186.29%4.13%3.47%-16.35%
201714.56%4.88%8.91%-0.55%
2016-18.85%2.66%13.44%-2.52%
Dividend
No Data Available

Asset Allocation
% Long% Short% Net Assets
Stock90.70%0.00%90.70%
Bond0.00%0.00%0.00%
Cash9.30%0.00%9.30%
Other0.00%0.00%0.00%
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
27.5523.2723.91
Sharpe Ratio
1.370.610.50
Sortino Ratio
3.271.120.79
Positive Months9.0019.0034.00
Negative Months3.0017.0025.00
Worst Month-7.45-11.47-18.29
World Regions
Region%
United States62.78
United Kingdom9.96
Eurozone9.09
Europe - ex Euro6.17
Canada1.81
Asia - Emerging0.88
Stock Sector Weighting
Sector% of Equity
Healthcare90.70
Top 10 Holdings
HoldingSectorCountry% of Assets
Regeneron Pharmaceuticals Inc HealthcareUnited States5.88
argenx SE HealthcareNetherlands5.19
Incyte Corp HealthcareUnited States4.88
Exelixis Inc HealthcareUnited States4.45
Vertex Pharmaceuticals Inc HealthcareUnited States4.19
Alexion Pharmaceuticals Inc HealthcareUnited States3.49
Synairgen PLC HealthcareUnited Kingdom2.74
Immunomedics Inc HealthcareUnited States2.71
Biomarin Pharmaceutical Inc HealthcareUnited States2.69
Genmab A/S HealthcareDenmark2.64
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Large
Size
Mid
Small
Value
Blend
Growth
Style
$
32.34
Closing Price
All key information and documents must be reviewed before being able to Invest.